Universal flu vaccine BiondVax goes robustly beyond first phase II trial
This article was originally published in Scrip
Executive Summary
The prospects of a "universal" flu vaccine becoming a pharmaceutical reality have received a boost with positive results from the first Phase II trial of an investigational product from the Israeli biotech company BiondVax Pharmaceuticals.